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Abstract 
RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in 
advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine 
tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes 
patients to previously effective but refractory platinum doublets after treatment with RRx-
001. The purpose of this case study is first to report a partial response to carboplatin and 
etoposide in a patient with small-cell lung cancer pretreated with RRx-001, indicating episen-
sitization or resensitization by epigenetic mechanisms, and second to discuss the literature 
related to small-cell lung cancer and episensitization. © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
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Introduction 
Small-cell lung cancer (SCLC), which comprises approximately 10–15% of all lung can-
cers [1], is a neuroendocrine tumor, previously known as oat cell carcinoma, that is closely 
linked with tobacco smoking [2] and characterized by an aggressive and rapid pattern of 
metastases, limited treatment options following progression, and overall poor prognosis [3]. 
The disease is traditionally divided into two stages: limited-stage disease (LD), confined to 
one hemithorax encompassable in a single radiation port, and extensive-stage disease (ED), 
extending beyond those boundaries [4], which comprise the vast majority of patients at ini-
tial diagnosis [5, 6]. For extensive-disease SCLC, the standard first-line regimen is etoposide-
platinum (EP) doublets followed by topotecan, approved for second-line treatment, since 
progression is the rule after first-line EP despite the fact that SCLC is initially chemosensitive 
(with response rates to first-line treatment on the order of 70–90% in LS disease and 50–
60% in ED disease [7]). In ED, despite a response rate of 15–28% [8] to topotecan [9], the 
median OS rarely exceeds 6 months. According to the current nomenclature [10], SCLC is 
categorized as ‘sensitive relapsed’ (PFS >3 months), ‘resistant’ (PFS <3 months) and ‘refrac-
tory’ (progression through first-line treatment). In general, subsequent readministration of 
EP doublets is contraindicated in resistant and refractory disease due to the likelihood of 
undue toxicities (myelosuppression and nephrotoxicity, for example) without benefit, since 
therapeutic resistance in these contexts is, with exceptions, construed as a stable and immu-
table trait [11]. No guidelines are available about platinum doublet rechallenge after initial 
and secondary failures. 
Pretreatment or priming with epigenetic inhibitors, like the approved DNA demethyla-
tors, e.g., 5-azacitidine (azacitidine, AZA) and 2′-deoxy-5-azacitidine (decitabine, DAC) and 
the histone deacetylases, e.g., vorinostat and romidepsin as well as experimental RRx-001, 
has been identified as a nascent strategy, still in its infancy, to attenuate or reverse re-
sistance to chemotherapy and immunotherapy [12–14], particularly in non-small cell and 
ovarian cancers. The term ‘episensitization [15]’ has been coined for this priming paradigm. 
RRx-001, in particular, has demonstrated evidence of episensitization to refractory irinotec-
an in the context of a Phase II clinical trial entitled ROCKET in metastatic colorectal cancer 
[16–18]. 
TRIPLE THREAT (NCT02489903) is an ongoing open-label Phase II trial in non-small 
lung cancer, SCLC and high-grade neuroendocrine tumors, which investigates a resensitiza-
tion strategy to previously administered, but now refractory, platinum doublets following 
treatment with and progression on (by RECIST vs. 1.1 criteria) single agent RRx-001 mixed 
ex vivo with 100 ml of autologous blood prior to infusion. The rationale for this unusual 
method of administration is related to the red blood cell partitioning of RRx-001, which 
binds with high affinity to a cysteine residue in the β-chain of Hb (Cys β93), displacing nitric 
oxide (NO) in the process. When NO is displaced in vivo via standard intravenous infusion, it 
stimulates venous nociceptors, with a mild to moderate sensation of pain or discomfort for 
patients; however, in the infusion bag, mixed with blood, the NO is reabsorbed by the red 
blood cells, which appears to completely abrogate the hyperalgesia, resulting in a well-
tolerated and rapid (~30 min) infusion.  
Herein, we report a case of a patient with extensive refractory ED-SCLC who was ‘epi-
sensitized’ to cisplatin and etoposide, with a partial response, after treatment with weekly 
intravenous RRx-001 autologous blood mix. 
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Case Report 
Patient 001–001, a 49-year-old male veteran, former smoker, with a diagnosis of exten-
sive-stage SCLC, completed six cycles of carboplatin and etoposide in December 2012. Hav-
ing progressed approximately 6 months later with ‘sensitive relapsed’ (PFS >3 months) dis-
ease, he was enrolled on a clinical trial at the NIH in July 2013 where he received six cycles of 
cisplatin and etoposide followed by maintenance with the HDAC inhibitor belinostat. Ap-
proximately 1 year after completion of the NIH trial, with symptoms of fatigue and inappe-
tence due to disease progression as well as dyspnea and decreased exercise tolerance from a 
large unilateral pleural effusion, he enrolled as the first patient (001–001) on the TRIPLE 
THREAT clinical trial at Walter Reed in June 2015. After the first dose of RRx-001, and con-
tinuing for the next 8–9 weeks, the patient reported a significantly increased appetite for and 
consumption of fried foods, specifically pork chops, and desserts, which led to dyspeptic 
symptoms. His fatigue, shortness of breath and exercise tolerance also significantly im-
proved to the point that he resumed uphill running and lifting weights. A CT scan at 6 weeks 
(fig. 1), correlating with the symptomatic improvement, demonstrated near complete resolu-
tion of the unilateral malignant pleural effusion. In addition, his target lesions shrank by 7% 
(not shown). 
Unfortunately, nearly 10 weeks after the start of TRIPLE THREAT, patient 001–001 de-
veloped ‘travelers thrombosis’ and pulmonary embolism presumably from a prolonged (10 
h) car ride, which prompted the PI to discontinue RRx-001 on suspicion of symptomatic 
progression since the patient began to complain of fatigue and inappetence as well as dysp-
nea associated to pulmonary embolism, even though repeat CT scans did not confirm radio-
logic progression. At this point, per protocol, since the patient still met all inclu-
sion/exclusion criteria, he was rechallenged for a third time with EP doublets and, despite 
expected toxicities of fatigue and anorexia, he reported improved performance status. At 6 
weeks after reintroduction of therapy, repeat CT scans demonstrated a partial response with 
an approximate 32% decrease in tumor size (fig. 2). One month later, a confirmatory scan 
showed a 50% decrease in tumor size, indicative of continued cytotoxic activity. 
Discussion 
To the best of our knowledge, TRIPLE THREAT is the first and only clinical trial to inves-
tigate resensitization or episensitization, since RRx-001 is an epigenetic inhibitor [19] in 
SCLC as well as NSCLC and neuroendocrine tumors. As a highly aggressive tumor with a uni-
formly dismal prognosis and an unmet need for effective therapeutic options, SCLC is ex-
tremely difficult to treat: the median survival time following recurrence rarely exceeds 6 
months, the 2-year survival is <10%, and there are virtually no 5-year survivors [20], requir-
ing innovative strategies to address the difficult challenge of salvage treatment of relapsed 
SCLC.  
DNA methyltransferase and HDAC inhibitors have demonstrated the potential to reverse 
therapeutic resistance [21] in multiple tumor types because epigenetic alterations, an im-
portant driver of carcinogenesis and progression, are, in theory, reversible. Paradoxically, 
these alterations are also stably maintained through mitotic cell division, leading to a kind of 
epigenetic memory [22], with priming of responses to temporally separate and subsequent, 
rather than simultaneous, therapy since the induced pattern of gene transcription persists.  
The clinical course of this SCLC patient (001–001) suggests, with the usual caveats about 
making generalizations from ‘n-of-1’ results, that reintroduction of etoposide-platinum after 
174 
 
Case Rep Oncol 2016;9:171–176 
DOI: 10.1159/000444631 
 
© 2016 The Author(s). Published by S. Karger AG, Basel 
www.karger.com/cro 
Carter et al.: RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a 
Partial Response after a Third Reintroduction of Platinum Doublets 
 
 
 
initial treatment with RRx-001, leading to episensitization, is a safe and effective strategy for 
solid tumor types previously treated with platinum doublet-based chemotherapy. The Phase 
II TRIPLE THREAT clinical trial is ongoing, having enrolled 5 patients to date, none of whom, 
besides patient 001–001, have progressed on RRx-001, and their data will also be reported, 
if episensitization, anticipated here as elsewhere, is demonstrated. 
Statement of Ethics 
The research behind this case report complies with the guidelines for human studies. 
Any subjects have given their informed consent in the study and the study protocol has been 
approved by the relevant institute’s institutional review board, also known as an independ-
ent ethics committee, ethical review board, or research ethics board. 
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Fig. 1. CT scans before and after treatment demonstrating a left-sided pleural effusion (a) before treat-
ment with RRx-001 and (b) its near complete resolution after 6 weeks. 
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Fig. 2. CT scans of the lungs demonstrating a significant reduction of target lesions (approximately 32% 
compared to baseline) 6 weeks after reintroduction of etoposide and cisplatin. Left: tumor scans after 
RRx-001. Right: tumor scans after etoposide and cisplatin treatment. 
 
